In a report issued on May 6, Evan Seigerman from BMO Capital maintained a Hold rating on Novo Nordisk, with a price target of $64.00. The company's shares closed last Friday at $67.35.

According to TipRanks.com, Seigerman is a 4-star analyst with an average return of

The word on The Street in general, suggests a Hold analyst consensus rating for Novo Nordisk with a $92.44 average price target.

According to TipRanks.com, Biliouris has currently 0 stars on a ranking scale of 0-5 stars, with an average return of

Beam Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $44.13, implying a 164.3% upside from current levels. In a report issued on May 6, William Blair also maintained a Buy rating on the stock.

According to TipRanks.com, Mukherjee has 0 stars on 0-5 stars ranking scale with an average return of

Currently, the analyst consensus on TScan Therapeutics is a Strong Buy with an average price target of $9.33, representing a 557.0% upside. In a report issued on May 6, TD Cowen also maintained a Buy rating on the stock.